| |
|
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive
Patients Following Once-daily Administration.
Calcagno A, Pinnetti C, De Nicolò A,
et al
Br J Clin Pharmacol. 2018 Feb 14
Abstract
Enantioselective and Regiodivergent Addition of Purines to
Terminal Allenes: Synthesis of Abacavir.
Thieme N, Breit B.
Angew Chem Int Ed Engl. 2017 Feb 1;56(6):
Abstract
Abacavir + dolutegravir + lamivudine for the treatment of
HIV.
Comi L, Maggiolo F.
Expert Opin Pharmacother. 2016 Sep 12
Abstract
Abacavir has no prothrombotic effect on platelets in vitro.
Diallo YL, Ollivier V, Joly V,
J Antimicrob Chemother. 2016 Aug 11.
Abstract
Short-term in vivo modifications of platelet NADPH oxidase 2
(NOX2) and prostaglandin in HIV-1 patients on abacavir-based therapies.
Pastori D, Esposito A, Carnevale R,
et al
HIV Med. 2016 May 10.
Abstract
Design, Synthesis and Biological Evaluation of Novel
Phosphorylated Abacavir Derivatives as Antiviral Agents Against Newcastle
Disease Virus Infection in Chicken.
K A S, Venkata Subbaiah KC, Lavanya R,
et al
Appl Biochem Biotechnol. 2016 May 3
Abstract
Development of albumin-based nanoparticles for the delivery of abacavir.
Wilson B, Paladugu L, Priyadarshini SR, Jenita JJ.
Int J Biol Macromol.
2015 Sep 10.
Abstract
Efficient synthesis of the intermediate of abacavir and carbovir using a
novel (+)-γ-lactamase as a catalyst.
Gao S, Zhu S, Huang R, et al
Bioorg Med Chem Lett.
2015 Jul 26
Abstract
FULL-TEXT ARTICLE
Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents
That Concern Prescribers and Patients:
A
Feasibility Study and Call for a Trial.
Achhra AC, Boyd MA, Law MG,
et al
PLoS One. 2014 Jun
26;9(6):e99530.
Paper
Homodimers of the Antiviral Abacavir as Modulators of
P-glycoprotein Transport in Cell Culture: Probing Tether Length.
Namanja HA, Emmert D,
Hrycyna CA, Chmielewski J.
Medchemcomm. 2013 Oct;4(10).
Abstract
Abacavir (Ziagen®) use between 2003 and 2008 in France
according to the electronic medical record NADIS®
Dellamonica P, Katlama C,
Lévy-Bachelot L, et al
Med
Mal Infect. 2013 Nov 18
Abstract
Bioactivation to an aldehyde metabolite-Possible role in the onset of toxicity
induced by the anti-HIV drug abacavir.
Grilo NM, Charneira C, Pereira SA, et al
Toxicol Lett. 2013 Nov 5.
Abstract
Structural and Thermodynamic Basis of Amprenavir/Darunavir and
Atazanavir Resistance in HIV-1 Protease with Mutations at Residue 50.
Mittal S, Bandaranayake RM, King NM, et al
J Virol.
2013 Jan 30.
Abstract |
Clinical pharmacogenetics implementation consortium guidelines
for hla-B genotype and abacavir dosing.
Martin MA, Klein TE, Dong BJ,
et al
Clin Pharmacol Ther.
2012 Apr;91(4):734-8
Abstract |
Enantioselective synthesis of the carbocyclic nucleoside
(-)-abacavir.
Boyle GA, Edlin CD,
Li Y, et al
Org Biomol Chem. 2012 Jan 25
Abstract |
Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or
oxidative stress genes in
coronary endothelial cells.
Kim C, Gupta SK, Green L,
et al
Antivir Ther.
2011;16(8):1335-9.
Abstract
Abacavir increases platelet reactivity via competitive
inhibition of soluble guanylyl cyclase.
Baum PD, Sullam PM, Stoddart
CA, McCune JM.
AIDS. 2011 Sep
21.
Abstract
Toward Eradicating HIV Reservoirs in the Brain: Inhibiting
P-glycoprotein at the
Blood-Brain Barrier with Prodrug Abacavir Dimers.
Namanja HA, Emmert D, Davis DA,
et al
J Am Chem Soc.
2011 Aug 25.
Abstract
Low-density lipoprotein size and lipoprotein-associated
phospholipase A2 in HIV-infected patients
switching to abacavir or tenofovir.
Saumoy M,
Ordoñez-Llanos J, Martínez E, et
al
Antivir Ther.
2011;16(4):459-468.
Abstract
Separation and characterization of forced degradation
products of abacavir sulphate by LC-MS/MS.
Rao RN, Vali RM,
Ramachandra B, Raju SS.
J Pharm Biomed Anal. 2010 Sep 22
Abstract |
Abacavir and didanosine induce the interaction between human leukocytes and
endothelial cells through Mac-1 upregulation.
De Pablo C, Orden S, Apostolova N,
et al
AIDS. 2010 May 6.
Abstract |
Near-Infrared Investigations of Novel Anti-HIV Tenofovir
Liposomes.
Zidan AS, Spinks C, Fortunak J,
et al
AAPS J. 2010 Mar 3.
Abstract |
Abacavir: pretreatment screening: warning. Encouraging method
but uncertainties remain.
[No authors listed]
Prescrire Int. 2008
Dec;17(98):239.
Abstract |
Current trends in screening across ethnicities for hypersensitivity to
abacavir.
Rodriguez-Nóvoa S, Soriano V.
Pharmacogenomics. 2008 Oct;9(10):1531-41.
Abstract |
Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to
confirmation to
clinical utility.
Hughes AR, Spreen WR, Mosteller M, et al
Pharmacogenomics J. 2008 Mar 11
Abstract
|
Association of genetic variations in HLA-B region with hypersensitivity to
abacavir in some, but not all, populations.
Hughes AR, Mosteller M, Bansal AT, et al
Pharmacogenomics.
2004 Mar;5(2):203-11.
Abstract
|
|
General
Reports
Perinatal
Data Index
Documents identified with this icon are in Portable Document Format (PDF)
and require the
